scholarly journals Prognostic Factors in Breast Cancer Patients with Brain Metastases: Retrospective Analysis

2018 ◽  
Vol 0 (0) ◽  
pp. 1-6
Author(s):  
Ramy Ghali ◽  
Ahmed Gaballah ◽  
Essam Saleh ◽  
Aamer Arif
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Breast Cancer Patients

Variation in prognostic factors in hormone receptor-positive breast cancer patients who responded to hormonal therapy and those who did not: A retrospective analysis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11514-11514
Author(s):  
A. Jain ◽  
P. Bapsy ◽  
S. V. Attili ◽  
U. Batra ◽  
L. Dasappa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Hormone Therapy ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Initial Diagnosis ◽  
Breast Cancer Patients ◽  
Hormone Receptor Positive ◽  
Hormonal Manipulation

11514 Background: Hormone receptor positive patents historically had a better prognosis than their receptor negative counterparts when other parameters are balanced. However not all the patients expressing Estrogen and progesterone respond well to the hormonal manipulation. Therefore we thought of doing a retrospective analysis of our hospital data to find out the differences in the prognostic factors in therapy responders and non responders. Methods: The study was conducted at tertiary care cancer center from India. Between 2002–2003 a total of 120 breast cancer patients who expressed either Estrogen receptor (ER) or progesterone receptor (PR) were analyzed. Only patients with metastatic breast cancer were analyzed. The patients were treated with our standard institutional protocol at the beginning according to the stage of the disease. The details and baseline characters were shown in table . Results: The responders tend to be post menopausal, having low grade, node negative tumors, expressed both ER and PR, and had long interval from the date of initial diagnosis. However tumor size and the site of metastasis (visceral vs. non visceral) did not alter the outcome to hormone therapy. Conclusion: patients who are having higher age, lower tumor grade, lower number of nodes, longer disease free interval after adjuvant therapy and expressing both receptors tend to respond to hormone therapy better than those who had the opposite characters. However as thought earlier, presence of visceral metastasis or larger tumors at the time of initial diagnosis dose not preclude response to hormonal manipulation. [Table: see text] No significant financial relationships to disclose.

scholarly journals PO101 PROGNOSTIC FACTORS AFTER GAMMA KNIFE RADIOSURGERY IN BREAST CANCER PATIENTS WITH BRAIN METASTASES

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S56
Author(s):  
Shoko Hayama ◽  
Osamu Nagano ◽  
Naohito Yamamoto ◽  
Takeshi Nagashima ◽  
Rikiya Nakamura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Breast Cancer Patients

scholarly journals Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Volker Rudat ◽  
Hamdan El-Sweilmeen ◽  
Iris Brune-Erber ◽  
Alaa Ahmad Nour ◽  
Nidal Almasri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Brain Metastases ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Developing Brain ◽  
Breast Cancer Patients

scholarly journals Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients

Cancer ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2587-2592 ◽  
Author(s):  
Dirk Rades ◽  
Radka Lohynska ◽  
Theo Veninga ◽  
Lukas J. A. Stalpers ◽  
Steven E. Schild
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Whole Brain Radiotherapy ◽  
Breast Cancer Patients ◽  
Whole Brain ◽  
Brain Radiotherapy

Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1079-1079 ◽  
Author(s):  
Paul W. Sperduto ◽  
Shane Mesko ◽  
Daniel Cagney ◽  
Eric Nesbit ◽  
Jason Chan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Prognostic Index ◽  
Tumor Subtype ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Luminal B ◽  
Therapeutic Decisions

1079 Background: Brain metastases (BM) are a common and fatal complication of breast cancer but survival varies widely based on various prognostic factors (PF). Hence, patient counseling and therapeutic decisions should be individualized. We previously published a prognostic index (Breast GPA) based on cohort A (1985-2007, n = 642), updated it with tumor subtype in cohort B (1993-2010, n = 400) and are now updating it with a larger contemporary cohort (C). Methods: A multi-institutional (19) multi-national (3) retrospective database of 2473 breast cancer patients with BM diagnosed from 1/1/2006-12/31/2017 was created and compared to our prior cohorts. Demographic, clinical, molecular factors, tumor subtype and treatment were correlated with survival. Kaplan-Meier survival estimates were calculated and compared with log-rank tests. Results: The median survival (MS) for cohorts A, B and C improved over time [12, 14 and 16 mo, respectively ( < 0.01)] despite the subtype distribution becoming less favorable: Luminal B (ER/PR/HER2+) decreased from 26% to 21%; HER2 (HER2+/ER/PR-) decreased from 31% to 17%, Luminal A (ER/PR+/HER2-) increased from 20% to 31%; Basal (ER/PR/HER2-) was unchanged at 24%.MS by subtype improved from 21 to 27 mo in Luminal B, 18 to 25 mo in HER2, 10 to 14 mo in Luminal A and 6 to 9 mo in Basal tumors. The number of BM was 1 in 35%, ≤4 in 67% and > 10 in 18%. PF significant for survival were tumor subtype, age, KPS, number of BM and extracranial metastases (ECM) (all < 0.01). Surprisingly, Hispanic women (7%) showed improved survival (p < 0.01). BRCA1 was mutated in 57/533 (11%) and those patients showed a trend (0.16) toward improved survival. Treatment patterns have changed: the use of whole brain radiation therapy decreased from 71% to 67% to 47% in cohorts A, B and C, respectively. Conclusions: Despite the shift to less favorable tumor subtypes, MS has improvedbut varies widely by diagnosis-specific PF. Compared to prior cohorts, number of BM and ECM were identified as new PF. Ethnic, genetic and treatment differences between the eras are apparent. The updated Breast GPA, based on these data, and the correlation between BRCA1 and tumor subtype will be presented.

Sign in / Sign up

Export Citation Format

Share Document